Daily cyclophosphamide for scleroderma: Are patients with the most to gain underrepresented in this trial?

American Journal of Respiratory and Critical Care Medicine

Volumn 176, Issue 10, 2007, Pages 952-953

  Wells, Athol U ^a   Latsi, Panagiota ^b   McCune, W Joseph ^c  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO;

AMENORRHEA; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDITORIAL; FOLLOW UP; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM EXPOSURE; LUNG ALVEOLITIS; LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MORTALITY; PILOT STUDY; PRIORITY JOURNAL; RELAPSE; REMISSION; SARCOIDOSIS; SCLERODERMA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEGENER GRANULOMATOSIS;

CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PATIENT SELECTION; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 36248975276     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200708-1185ED     Document Type: Editorial

References (16)

1. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040-1047.
2. Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, Alberra C, Brutsche M, Davis G, Donohue JF, et al., for the Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006;174:795-802.
3. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, et al., for the Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-2666.
4. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, Arriola E, Strange C, Bolster MB, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007;176:1026-1034.
5. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962-3970.
6. Martinez FJ, McCune WJ. Cyclophosphamide for scleroderma lung disease. N Engl J Med 2006;354:2707-2709.
7. McCarthy CJ, Sheldon S, Ross CW, McCune WJ. Cytogenetic abnormalities and therapy-related myelodysplastic syndromes in rheumatic disease. Arthritis Rheum 1998;41:1493-1496.
8. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991;34:945-950.
9. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-498.
10. Austin HA III, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, Decker JL. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-619.
11. Ognenovski VM, Marder W, Somers EC, Johnston CM, Farrehi JG, Selvaggi SM, McCune WJ. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol 2004;31:1763-1767.
12. Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005;52:2761-2767.
13. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-980.
14. Wegener's Granulomatosis Etanercept Trial Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-361.
15. Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 2006;8:R182.
16. McCune WJ. Mycophenolate mofetil for lupus nephritis. N Engl J Med 2005;353:2282-2284.